The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1088 Ozempic articles
Influencer Brianna 'Chickenfry' LaPaglia's TikTok blast—'You're gonna die. You're all gonna die.'—targets Ozempic use among those who 'do not need' it, sparking viral debate. Page Six coverage highlights three colliding pressures amid Baptist Health's side effect warnings. Her personal recovery from disordered eating adds weight to the caution.
India's CDSCO has issued a strict advisory against misleading promotions of prescription obesity drugs like GLP-1 receptor agonists. The regulator targets indirect ads, exaggerated claims, and efforts undermining lifestyle changes. This move reinforces ethical marketing and patient safety in obesity treatment.
Fat tissue isn't just storage—it's a dynamic organ that can burn energy as heat, opening new doors for weight loss beyond appetite-suppressing drugs like Ozempic and Wegovy. Researchers are targeting brown and beige fat to boost calorie burn without triggering hunger. This could be the next era in metabolic therapies.
Netflix's Vladimir stars Rachel Weisz as a 56-year-old consumed by desire, echoing a secret midlife libido explosion many women are experiencing. Attributed to surging HRT use and GLP-1 weight loss injections, this trend is reshaping confidence and relationships. From cultural hits to real-life chats, explore why midlife women feel hotter than ever.
The Indian government has issued a strict advisory cautioning pharmaceutical companies against surrogate advertising to promote GLP-1 drugs, amid fears of consumer misuse. Signed by Drugs Controller General Rajeev Singh Raghuvanshi on March 10, the note prohibits all direct or indirect promotions on any platform. This comes as Ozempic and Wegovy patents near expiry, potentially flooding the market with generics.
Semaglutide, the powerhouse behind Ozempic and Wegovy, might soon become dramatically more affordable. A recent study reveals generic versions could cost as little as $28 per person-year after patents expire in 2026. This could transform access to treatment for obesity and type 2 diabetes globally.
An observational study in the British Medical Journal reveals GLP-1 medications like semaglutide significantly lower substance use disorder (SUD) risk in US veterans with type 2 diabetes. Compared to SGLT2 inhibitors, GLP-1s reduced new addiction risks by up to 25% and improved outcomes like 50% fewer substance-related deaths. These findings challenge traditional views on addiction and metabolic health.
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
Contrary to predictions, chocolate sales are surging among GLP-1 weight-loss drug users in the U.S., according to Swiss chocolatier Lindt & Spruengli. An internal analysis reveals these households account for 17.5% of chocolate purchases, with premium varieties rising nearly 17%. This challenges assumptions about appetite suppression from drugs like Ozempic and Mounjaro.
